TABLE 1.
Characteristic of included studies in meta‐analysis.
| Study | Country | Study design | Sex | Trial duration (week) | Participants | Means age | Means BMI | Intervention | Sample size | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IG | CG | IG | CG | Treatment group | Intervention dose (gr/day) | Control | IG | CG | ||||||
| El‐Sayed (2011) | Yemen | parallel, R, PC, DB | M/F (F: 10, M: 20) | 8 | Type 2 Diabetes | 40 ± 17.52 | 40 ± 17.52 | 31.03 ± 3.8 | 32.27 ± 5.2 | purslane | 10 | metformin | 15 | 15 |
| Moradi et al. (2012) | Iran | Parallel, R | M/F: 93 | 8 | Hypercholesterolemia patients | 44 ± 9.6 | 49 ± 11.6 | 27 ± 3.9 | 26 ± 4.9 | purslane | 50 | lovastatin | 41 | 52 |
| Rafiee Vardanjani et al. (2013) | Iran | parallel, R, PC, DB | M/F: 60 | 8 | Schizophrenic Patients | 43.76 ± 10.96 | 45.26 ± 10.03 | NR | NR | purslane | 1 | control diet | 30 | 30 |
| Farzanegi (2014) | Iran | parallel, R, PC | F: 14 | 8 | Type 2 Diabetes | 51.17 ± 4.88 | 50.83 ± 6.79 | 29.88 ± 4.34 | 30.71 ± 4.34 | purslane & Exercise | 7.5 | control diet & Exercise | 7 | 7 |
| Farzanegi (2014) | Iran | parallel, R, PC | F: 14 | 8 | Type 2 Diabetes | 52.33 ± 4.08 | 50.17 ± 5.34 | 29.01 ± 4.34 | 29.37 ± 4.55 | purslane | 7.5 | control diet | 7 | 7 |
| Fakoori Jouibari et al. (2014) | Iran | parallel, R, PC, DB | F: 14 | 8 | Type 2 Diabetes | 50 | 50 | NR | NR | purslane | 7.5 | control diet | 7 | 7 |
| Fakoori Jouibari et al. (2014) | Iran | parallel, R, PC, DB | F: 14 | 8 | Type 2 Diabetes | 50 | 50 | NR | NR | purslane & Exercise | 7.5 | control diet & Exercise | 7 | 7 |
| Zakizadeh et al. (2015) | Iran | Crossover, R, PC | M/F: 40 | 5 | Type 2 Diabetes | 35–65 | 35–65 | NR | NR | purslane | 10 | control diet | 40 | 40 |
| Esmaillzadeh et al. (2015) | Iran | Crossover, R, PC | M/F: 48 | 5 | Type 2 Diabetes | 51.4 ± 6.09 | 51.4 ± 6.09 | 28.99 ± 3.9 | 28.8 ± 3.9 | purslane | 10 | control diet | 48 | 48 |
| Adelnia Najafabadi et al. (2015) | Iran | parallel, R, PC, B | M/F (F: 12, M: 42) | 8 | Non‐alcoholic fatty liver disease | 54.7 ± 9.52 | 39.891 ± 8.84 | 32.77 ± 3.63 | 31.08 ± 3.24 | purslane | 10 | control diet | 27 | 27 |
| Dehghan et al. (2016) | Iran | parallel, R, PC, DB | F: 98 | 16 | Type 2 Diabetes | 52.33 ± 4.08 | 50.17 ± 5.34 | 29 ± 5 | 29.9 ± 7.3 | purslane | 7.5 | Placebo | 49 | 49 |
| Dehghan et al. (2016) | Iran | parallel, R, PC, DB | F: 98 | 16 | Type 2 Diabetes | 61.17 ± 4.88 | 58.83 ± 6.79 | 29.8 ± 6.4 | 29.5 ± 7.2 | purslane & Aerobic Training | 7.5 | placebo & Aerobic Training | 49 | 49 |
| Wainstein et al. (2016) | Israel | parallel, R, PC, DB | M/F (F: 22, M: 41) | 12 | Type 2 Diabetes | 52.4 ± 7.9 | 58.3 ± 10.8 | 29.9 ± 3.8 | 29.1 ± 3.6 | purslane | 0.18 | placebo | 31 | 32 |
| Marjan Bedakhanian et al. (2017) | Iran | parallel, R, PC | M: 78 | 8 | Metabolic Syndrome | 46.5 ± 7.6 | 47.8 ± 6.5 | 28.38 ± 1.79 | 28.57 ± 2.15 | purslane | 0.06 | control diet | 39 | 39 |
| Gheflati et al. (2019) | Iran | parallel, R, PC | M/F (F: 48, M: 12) | 8 | Non‐alcoholic fatty liver disease | 40.07 ± 9.52 | 39.81 ± 8.84 | 32.77 ± 3.63 | 31.09 ± 3.24 | purslane | 10 | control diet | 27 | 27 |
| Ghorbanian et al. (2019) | Iran | parallel, R, PC | F: 20 | 8 | Non‐Active Girls | 20–30 | 20–30 | 27 ± 2.6 | 28.21 ± 9.8 | purslane | 1.2 | control diet | 10 | 10 |
| Papoli et al. (2019) | Iran | parallel, R, PC | F: 64 | 12 | Metabolic syndrome | 42.16 ± 5.48 | 43.16 ± 8.33 | 28.23 ± 4.43 | 26.3 ± 3.72 | purslane | 10 | control diet | 32 | 32 |
| Darvish Damavandi et al. (2021) | Iran | parallel, R, PC, DB | M/F (F: 31, M: 43) | 12 | Non‐alcoholic fatty liver disease | 46.18 ± 9.71 | 46.05 ± 10.09 | 31.56 ± 3.78 | 31.83 ± 3.97 | purslane | 0.3 | Placebo | 37 | 37 |
| Delvarianzadeh et al. (2021) | Iran | parallel, R, PC, DB | M/F (F: 51, M: 53) | 4 | Type 2 Diabetes | 53.5 ± 6.75 | 53.6 ± 6.34 | NR | NR | purslane | 10 | control diet | 54 | 50 |
Abbreviations: CG, control group; F, Female; IG, intervention group; M, Male; NR, not reported; NR, not reported.